GLP-2 (TIRZ)

This compound is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, representing an innovative approach in metabolic research. This synthetic peptide combines the mechanisms of two incretin hormones, offering researchers a unique tool to study combined hormonal effects on metabolism. Scientific investigations focus on how dual incretin activation affects insulin secretion, glucagon levels, appetite regulation, energy expenditure, and overall metabolic homeostasis. Researchers examine the synergistic effects of GIP and GLP-1 receptor activation, comparing outcomes to single-agonist approaches. Studies explore its impact on pancreatic function, adipose tissue metabolism, hepatic glucose production, and cardiovascular parameters. The compound is particularly valuable for understanding the complex interplay between different incretin pathways and their combined effects on whole-body metabolism and energy balance.